|The FARS2 n/a (Catalog #MBS649347) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The FARS2 (FARS1, Phenylalanine-tRNA Ligase, Mitochondrial, Phenylalanyl-tRNA Synthetase) reacts with Human and may cross-react with other species as described in the data sheet. MyBioSource\'s FARS2 can be used in a range of immunoassay formats including, but not limited to, ELISA (EL/EIA), Western Blot (WB).
Suitable for use in ELISA and Western Blot. Researchers should empirically determine the suitability of the FARS2 n/a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. The amino acid sequence is listed below:
KVKFQPLSKY PAVINDISFW LPSENYAEND FYDLVRTIGG DLVEKVDLID KFVHPKTHKT SHCYRITYRH MERTLSQREV RHIHQALQEA AVQLLGVEGR F.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
FARS2 encodes a telomere specific protein which is a component of the telomere nucleoprotein complex. This protein is present at telomeres throughout the cell cycle and functions as an inhibitor of telomerase, acting in cis to limit the elongation of individual chromosome ends. The protein structure contains a C-terminal Myb motif, a dimerization domain near its N-terminus and an acidic N-terminus.
Immunogen: Partial recombinant corresponding to aa351-451 from FARS2 (NP_006558) with GST tag. MW of the GST tag alone is 26kD. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing FARS2 are readily searchable from our website. Different antibodies against the same target such as FARS2 may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.